PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers

by Elizabeth K. Lee, Panagiotis A. Konstantinopoulos
Published 2020-07-01

Current status and evolution of preclinical drug development models of epithelial ovarian cancer

by Panagiotis A Konstantinopoulos, Ursula A Matulonis
Published 2013-12-01

The Molecular Basis of Retinoids’ Use in Breast Cancer Chemoprevention

by Michalis V. Karamouzis, Panagiotis A. Konstantinopoulos, Athanasios G. Papavassiliou
Published 2007-01-01

Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations

by Sachet A. Shukla, Brooke E. Howitt, Catherine J. Wu, Panagiotis A. Konstantinopoulos
Published 2017-02-01

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure

by Elizabeth K. Lee, Neal I. Lindeman, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos
Published 2019-05-01

EGF-R is Expressed and AP-1 and NF-κ:B Are Activated in Stromal Myofibroblasts Surrounding Colon Adenocarcinomas Paralleling Expression of COX-2 and VEGF

by Panagiotis A. Konstantinopoulos, Gerasimos P. Vandoros, Michalis V. Karamouzis, Maria Gkermpesi, Georgia Sotiropoulou-Bonikou, Athanasios G. Papavassiliou
Published 2007-01-01

Leiomyosarcoma of the Prostate: Case Report and Review of 54 Previously Published Cases

by Gerasimos P. Vandoros, Theodoros Manolidis, Michalis V. Karamouzis, Maria Gkermpesi, Maria Lambropoulou, Athanasios G. Papatsoris, Ioannis Zachos, Panagiotis A. Konstantinopoulos
Published 2008-01-01

Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance.

by Panagiotis A Konstantinopoulos, Elena Fountzilas, Jeffrey D Goldsmith, Manoj Bhasin, Kamana Pillay, Nancy Francoeur, Towia A Libermann, Mark C Gebhardt, Dimitrios Spentzos
Published 2010-01-01

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas

by Khyati Meghani, Walker Fuchs, Alexandre Detappe, Pascal Drané, Ewa Gogola, Sven Rottenberg, Jos Jonkers, Ursula Matulonis, Elizabeth M. Swisher, Panagiotis A. Konstantinopoulos, Dipanjan Chowdhury
Published 2018-04-01

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

by Elizabeth K. Lee, Zhenying Tan-Wasielewski, Ursula A. Matulonis, Michael J. Birrer, Alexi A. Wright, Neil Horowitz, Panagiotis A. Konstantinopoulos, Jennifer Curtis, Joyce F. Liu
Published 2019-08-01

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression

by Brooke E. Howitt, Kyle C. Strickland, Lynette M. Sholl, Scott Rodig, Lauren L. Ritterhouse, Dipanjan Chowdhury, Alan D. D'Andrea, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos
Published 2017-02-01

Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer.

by Panagiotis A Konstantinopoulos, Stephen A Cannistra, Helen Fountzilas, Aedin Culhane, Kamana Pillay, Bo Rueda, Daniel Cramer, Michael Seiden, Michael Birrer, George Coukos, Lin Zhang, John Quackenbush, Dimitrios Spentzos
Published 2011-03-01

Epstein–Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation

by Hai Hu, Man-Li Luo, Christine Desmedt, Sheida Nabavi, Sina Yadegarynia, Alex Hong, Panagiotis A. Konstantinopoulos, Edward Gabrielson, Rebecca Hines-Boykin, German Pihan, Xin Yuan, Christos Sotirious, Dirk P. Dittmer, Joyce D. Fingeroth, Gerburg M. Wulf
Published 2016-07-01

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer

by Young Eun Choi, Khyati Meghani, Marie-Eve Brault, Lucas Leclerc, Yizhou J. He, Tovah A. Day, Kevin M. Elias, Ronny Drapkin, David M. Weinstock, Fanny Dao, Karin K. Shih, Ursula Matulonis, Douglas A. Levine, Panagiotis A. Konstantinopoulos, Dipanjan Chowdhury
Published 2016-01-01

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

by Liya Ding, Hye-Jung Kim, Qiwei Wang, Michael Kearns, Tao Jiang, Carolynn E. Ohlson, Ben B. Li, Shaozhen Xie, Joyce F. Liu, Elizabeth H. Stover, Brooke E. Howitt, Roderick T. Bronson, Suzan Lazo, Thomas M. Roberts, Gordon J. Freeman, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Jean J. Zhao
Published 2018-12-01

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13

by Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, Behnam Nabet, Mousheng Xu, Yanke Liang, Chunshan Quan, Jinhua Wang, Mingfeng Hao, Sangeetha Palakurthi, Shan Zhou, Qing Zeng, Paul T Kirschmeier, Khyati Meghani, Alan L Leggett, Jun Qi, Geoffrey I Shapiro, Joyce F Liu, Ursula A Matulonis, Charles Y Lin, Panagiotis A Konstantinopoulos, Nathanael S Gray
Published 2018-11-01

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

by Panagiotis A. Konstantinopoulos, Alexandre André B. A. da Costa, Doga Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Bose Kochupurakkal, David L. Kolin, Elise C. Kohn, Joyce F. Liu, Elizabeth H. Stover, Jennifer Curtis, Nabihah Tayob, Madeline Polak, Dipanjan Chowdhury, Ursula A. Matulonis, Anniina Färkkilä, Alan D. D’Andrea, Geoffrey I. Shapiro
Published 2021-09-01

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

by Anniina Färkkilä, Doga C. Gulhan, Julia Casado, Connor A. Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro, Yinghui Zhou, Julie R. Graham, Bruce J. Dezube, Pamela Munster, Sandro Santagata, Elizabeth Garcia, Scott Rodig, Ana Lako, Dipanjan Chowdhury, Geoffrey I. Shapiro, Ursula A. Matulonis, Peter J. Park, Sampsa Hautaniemi, Peter K. Sorger, Elizabeth M. Swisher, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos
Published 2020-03-01

Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

by Anniina Färkkilä, Doga C. Gulhan, Julia Casado, Connor A. Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro, Yinghui Zhou, Julie R. Graham, Bruce J. Dezube, Pamela Munster, Sandro Santagata, Elizabeth Garcia, Scott Rodig, Ana Lako, Dipanjan Chowdhury, Geoffrey I. Shapiro, Ursula A. Matulonis, Peter J. Park, Sampsa Hautaniemi, Peter K. Sorger, Elizabeth M. Swisher, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos
Published 2020-05-01